10-K: Kiromic BioPharma Reports 2023 Results, Advances Deltacel Clinical Trial

Kiromic BioPharma's 2023 annual report highlights progress in its Deltacel clinical trial and ongoing financial challenges.

Summary

• Kiromic BioPharma, a clinical-stage biotherapeutics company, reported a net loss of $20.9 million for 2023, compared to a $34.7 million loss in 2022.
• The company's cash used in operating activities was $21.2 million in 2023.
• As of December 31, 2023, Kiromic had an accumulated deficit of $122.9 million.
• Kiromic is focused on developing allogeneic Gamma Delta T-cell therapies for solid tumors.
• The company's lead product candidate, Deltacel, is in Phase 1 clinical trials for non-small cell lung cancer.
• Kiromic is also developing engineered GDT cell therapies, Procel and Isocel, which are currently in preclinical development.
• The company expects to submit IND applications for Procel and Isocel in the first half of 2025, subject to financing.
• Kiromic's proprietary target discovery engine, Diamond, uses AI to identify cancer-specific immunotherapy targets.
• The company is developing virus-free cell engineering methods to develop novel therapies for solid tumors.
• Kiromic is also developing a simple test to pre-screen donors to identify those whose GDT cells have the most efficient expansion and activation potential.
• The company is developing a third module of the Diamond platform to predict which patients will best respond to GDT cell therapies.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in clinical trials and technological development, the company's financial situation and going concern status are significant concerns. The company is also facing legal challenges and intense competition.

Positives

• The Deltacel-01 clinical trial has commenced, with initial results showing promise.
• Kiromic's proprietary Diamond platform and virus-free engineering tools are innovative.
• The company's allogeneic, off-the-shelf manufacturing process has the potential to reduce costs and lead times.
• Preclinical data suggests that Kiromic's GDT therapies are safe and effective.
• The company is expanding its clinical trial sites for Deltacel-01.

Negatives

• Kiromic has incurred significant losses since inception and expects to continue to incur losses.
• The company has not generated any revenue to date and may never achieve profitability.
• Kiromic's financial situation raises substantial doubt about its ability to continue as a going concern.
• The company will need substantial additional funding to continue operations.
• There is no guarantee that additional capital will be available on acceptable terms.
• The company has a limited operating history and has never commercialized a product.
• The regulatory approval process for Kiromic's product candidates is lengthy and time-consuming.
• The company faces substantial competition from other pharmaceutical and biotechnology companies.
• The market opportunities for Kiromic's product candidates may be smaller than estimated.

Risks

• Kiromic may be forced to delay, reduce, or eliminate research programs if it cannot raise additional capital.
• The company's tumor-specific cancer immunotherapy approach is novel and unproven.
• Clinical trials may be delayed or prevented due to difficulties in patient enrollment.
• Preliminary data from clinical trials may change as more data becomes available.
• Product liability lawsuits could cause substantial liabilities.
• Manufacturing problems could result in delays in development or commercialization.
• The company may not be able to obtain sufficient quantities of raw materials and supplies.
• The FDA may disagree with Kiromic's regulatory plan and may not approve its product candidates.
• The company may not be able to obtain or maintain orphan drug designation.
• Kiromic's relationships with third parties may be subject to healthcare fraud and abuse laws.
• The company may not be able to adequately protect its intellectual property rights.
• The company's common stock may be volatile or may decline regardless of operating performance.
• The company does not expect to pay dividends in the foreseeable future.
• Stockholders may experience substantial dilution if the company issues additional shares.
• Cybersecurity breaches could expose the company to liability and affect its business and reputation.
• The company may be subject to securities laws claims regarding past disclosures.
• Increased political uncertainty could have a material adverse effect on the company's business.

Future Outlook

Kiromic expects to continue to incur losses and will need substantial additional funding to continue operations. The company plans to submit IND applications for Procel and Isocel in the first half of 2025, subject to financing. Kiromic also plans to apply for breakthrough designation for Deltacel in the summer of 2024 if preliminary efficacy is shown.

Management Comments

• Management anticipates that existing cash resources will not be sufficient to meet operating and liquidity needs beyond mid-June 2024.
• Management is currently evaluating various cost reduction actions, including additional reductions in the Company's workforce and suspending research and development expenditures on one or more product candidates, in order to reduce the Company's expenditures and preserve cash.

Industry Context

The document highlights Kiromic's position in the competitive field of cancer immunotherapy, particularly in the development of allogeneic cell therapies. The company is targeting solid tumors, which represent a significant portion of cancer cases. The document also mentions the growing CAR-T cell therapy market and the potential for allogeneic therapies to address limitations of autologous approaches.

Comparison to Industry Standards

• Kiromic is competing with established companies like Novartis and Gilead (Kite) in the CAR-T cell therapy space, as well as other companies developing allogeneic T-cell therapies such as Atara Biotherapeutics and Allogene Therapeutics.
• The company is also competing with companies developing GDT cell therapies such as Adicet Bio and Lava Therapeutics.
• Kiromic's approach of using non-engineered and engineered GDT cells, combined with low-dose radiation, is unique compared to many competitors.
• The company's focus on targeting PD-L1 and Mesothelin isoforms is also a differentiating factor.
• Kiromic's in-house cGMP manufacturing capabilities are intended to provide a competitive advantage in terms of cost and lead time compared to companies relying on third-party manufacturers.
• The company's use of AI in target discovery through its Diamond platform is also a differentiating factor compared to traditional methods.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in ongoing litigation with Jason Terrell, a former consultant and director.
• The company is also involved in a class action lawsuit related to alleged securities violations.
• The company has reached a settlement in principle to resolve the class action lawsuit.
• The company received a Grand Jury Subpoena from the U.S. Department of Justice requesting certain information.

Stakeholder Impact

• Shareholders face the risk of substantial dilution and potential loss of investment.
• Employees may be affected by potential workforce reductions.
• Customers (patients) may benefit from the development of new therapies, but clinical trials are still in early stages.
• Suppliers and creditors may be affected by the company's financial instability.

Next Steps

• Continue the Deltacel-01 Phase 1 clinical trial and enroll additional patients.
• Activate additional clinical trial sites for Deltacel-01.
• Continue the development of Isocel and Procel.
• Submit IND applications for Procel and Isocel in the first half of 2025, subject to financing.
• Apply for breakthrough designation for Deltacel in the summer of 2024 if preliminary efficacy is shown.
• Seek additional financing to continue operations and fund research and development.

Key Dates

Keywords

Gamma Delta T-cell therapy, solid tumors, immunotherapy, Deltacel, Procel, Isocel, clinical trials, AI targeting, biotherapeutics, cancer, PD-L1, Mesothelin, cGMP, Diamond platform, allogeneic